For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Cronos Group (CRON) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cronos Group is a member of the Medical sector. This group includes 916 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Cronos Group is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CRON's full-year earnings has moved 200% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CRON has returned 27.4% so far this year. Meanwhile, stocks in the Medical group have gained about 6.3% on average. This shows that Cronos Group is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Amgen (AMGN). The stock has returned 34.2% year-to-date.
In Amgen's case, the consensus EPS estimate for the current year increased 2.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Cronos Group is a member of the Medical - Drugs industry, which includes 133 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have lost 2.1% this year, meaning that CRON is performing better in terms of year-to-date returns.
On the other hand, Amgen belongs to the Medical - Biomedical and Genetics industry. This 449-stock industry is currently ranked #100. The industry has moved +5.9% year to date.
Cronos Group and Amgen could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cronos Group Inc. (CRON): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).